Pre-clinical tests of the vaccine showed a positive immune response, the London-based maker of Lucky Strike cigarettes said in a statement ZURICH : An experimental Covid-19 vaccine developed by cigarette maker British American Tobacco Plc is poised to begin testing in humans.
Pre-clinical tests of the vaccine showed a positive immune response, the London-based maker of Lucky Strike cigarettes said Friday in a statement.
The first phase of human trials could begin as soon as late June if authorized by drug regulators, BAT said. Drugmakers from around the world have jumped into the vaccine race, with more than 100 candidates in development in the US, Europe, China and other regions.